Following a registered protocol, it evaluates the effectiveness and safety of intravenous albumin, with or without diuretics, versus no albumin in hospitalised children aged 1-18 years with nephrotic syndrome and oedema. This evidence concerns the gene ALB and nephrotic syndrome.